Radiosensitivity of neuroendocrine cancer cells to 177Lu-DOTATATE and radiobiological implications for peptide radionuclide therapy

被引：0
|
作者：
Tamborino, G. [1 ,2 ]
Engbers, P. [1 ,2 ]
de Wolf, T. [1 ,2 ]
Reuvers, T. [1 ,2 ]
Konijnenberg, M. [1 ]
Nonnekens, J. [1 ,2 ]
机构：
[1] Erasmus MC, Dept Radiol & Nucl Med, Rotterdam, Netherlands
[2] Erasmus MC, Dept Mol Genet, Rotterdam, Netherlands
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023年 / 50卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-146
引用
收藏
页码：S66 / S66
页数：1
相关论文
共 50 条
  • [31] 177Lu-Dotatate for midgut neuroendocrine tumours
    Burki, Talha Khan
    LANCET ONCOLOGY, 2017, 18 (02): : E74 - E74
  • [32] Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome
    Zandee, Wouter T.
    Brabander, Tessa
    Blazevic, Anela
    Minczeles, Noemie S.
    Feelders, Richard A.
    de Herder, Wouter W.
    Hofland, Johannes
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (09): : E3665 - E3672
  • [33] Towards a quality assurance for dosimetry in peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE
    Marin, G.
    Vanderlinden, B.
    Wimana, Z.
    Guiot, T.
    Karfis, I.
    Flamen, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S159 - S160
  • [34] Preliminary results of 177Lu-DOTATATE radionuclide therapy in patients with medullary thyroid cancer
    Lobo Lopes, F. P. P.
    Vaisman, F.
    de Souza Machado Neto, L.
    de Castro, P. H. R.
    Bulzico, D. A.
    Vilhena, B.
    Carneiro, M.
    Corbo, R.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56
  • [35] Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) with 177Lu-Dotatate (Lutathera) (LU) in neuroendocrine tumors (NETs)
    Navarro Martin, M.
    Teran Brage, E.
    Campana-Diaz, E.
    Garcia-Talavera, P.
    Reguera Puertas, P.
    Rama-Alonso, S.
    Garijo-Martinez, M. C.
    Felix, L. C.
    Diaz Sanchez, P.
    Vidal Tocino, R.
    Fonseca Sanchez, E.
    ANNALS OF ONCOLOGY, 2024, 35 : S95 - S95
  • [36] Assessing neuroendocrine tumour response to peptide receptor radionuclide therapy with 177Lu-DOTATATE using voxel-based dosimetry
    Ram, L.
    Bissell, S.
    Hughes, S.
    Ross, E.
    Geh, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S395 - S395
  • [37] Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients
    Minczeles, Noemie S.
    de Herder, Wouter W.
    Feelders, Richard A.
    Verburg, Frederik A.
    Hofland, Johannes
    Brabander, Tessa
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (01) : 40 - 46
  • [38] Lu-177-DOTATATE Peptide Receptor Radionuclide Therapy
    Abbott, Amanda
    Jacene, Heather
    JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2018, 46 (03) : 245 - 246
  • [39] Excellent Response to 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in a Patient With Progressive Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation After 177Lu-PSMA Therapy
    Liu, Chen
    Liu, Teli
    Zhang, Jingjing
    Baum, Richard P.
    Yang, Zhi
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (11) : 876 - 878
  • [40] Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
    Bodei, Lisa
    Cremonesi, Marta
    Grana, Chiara M.
    Fazio, Nicola
    Iodice, Simona
    Baio, Silvia M.
    Bartolomei, Mirco
    Lombardo, Dario
    Ferrari, Mahila E.
    Sansovini, Maddalena
    Chinol, Marco
    Paganelli, Giovanni
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (12) : 2125 - 2135
12345